MedPath

Liothyronine

Generic Name
Liothyronine
Brand Names
Cytomel, Np Thyroid
Drug Type
Small Molecule
Chemical Formula
C15H12I3NO4
CAS Number
6893-02-3
Unique Ingredient Identifier
06LU7C9H1V

Overview

Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.

Background

Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.

Indication

Liothyronine is officially approved for the following indications: In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels. The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy. Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.

Associated Conditions

  • Autonomy of thyroid gland
  • Hyperthyroidism
  • Hypothyroidism
  • Myxedema coma
  • Thyroid Cancer
  • Euthyroid Goitre
  • Myxedema pre-coma

FDA Approved Products

Liothyronine Sodium
Manufacturer:Preferred Pharmaceuticals Inc.
Route:ORAL
Strength:5 ug in 1 1
Approved: 2023/07/21
NDC:68788-7269
Liothyronine sodium
Manufacturer:Biocon Pharma Inc.
Route:ORAL
Strength:25 ug in 1 1
Approved: 2024/02/23
NDC:70377-115
liothyronine sodium
Manufacturer:Sun Pharmaceutical Industries, Inc.
Route:ORAL
Strength:5 ug in 1 1
Approved: 2023/06/29
NDC:62756-589
Adthyza thyroid
Manufacturer:Azurity Pharmaceuticals, Inc.
Route:ORAL
Strength:13.5 ug in 1 1
Approved: 2023/02/17
NDC:24338-097
Liothyronine Sodium
Manufacturer:A-S Medication Solutions
Route:ORAL
Strength:5 ug in 1 1
Approved: 2023/01/10
NDC:50090-3131

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath